# Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

> **NCT02100228** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 1500 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Parenteral heparin and/or oral Vitamin K antagonist

## Key facts

- **NCT ID:** NCT02100228
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-14
- **Primary completion:** 2017-02-08
- **Final completion:** 2017-02-08
- **Target enrollment:** 1500 (ACTUAL)
- **Last updated:** 2018-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100228, "Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02100228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*